Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis

Sponsor
Tampere University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05902455
Collaborator
Olfactomics Oy (Other)
40
1
48.2
0.8

Study Details

Study Description

Brief Summary

The trial is a single-center, non-randomized feasibility study aiming to evaluate the feasibility of ex-vivo tissue analysis using differential mobility spectrometry (DMS) of tissue smoke generated by the use of an electrosurgical instrument.

Patients recruited in the trial receive standard-of-care oral squamous cell carcinoma tumor excision surgery.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Punch biopsy

Detailed Description

Oral squamous cell carcinoma is the sixth common carcinoma and the cause of 1-2% of cancer related deaths in the world. The incidence of oral squamous cell carcinoma was 255 cases in Finland and 742 270 cases worldwide in year 2015. The number of cases per year has been increasing. The approximate age of tumor occurrence is usually between 60 - 70 years. The 5-year survival rate of all diagnosed oral squamous cell carcinoma cases in Finland during the years between 2014 and 2016 was 67% for women and 61% for men.(1,2)

Early diagnostics is relevant, since oral squamous cell carcinoma tumors have a tendency to grow rapidly and metastasize early to regional lymphnodes and later on to lungs, liver and bones. Typical locations of the tumor are tongue, gums and sole of mouth.(1,2)

The primary treatment option for oral squamous cell carcinoma is surgical removal of the tumor with 0,5 - 1cm healthy tissue margin (3,4,5,6). The aim of the operation is to remove the tumor entirely so that the healthy tissue margins are as sparing as possible and that the functional and cosmetic outcomes are as satisfactory as possible. Sufficient healthy tissue margin is one of the most important prognostic factors (3). Nevertheless, there is only little evidence based knowledge of sufficient healthy tissue margins.

Differential mobility spectrometry (DMS) based application called automatic tissue analysis (ATAS) can be utilized to identify tumor cells from healthy tissue. Tissue identification is done by analyzing tissue smoke that is generated by the use of an electrosurgical instrument called diathermy (7,8).

The objective of the trial is to test whether it is possible to identify oral squamous cell carcinoma tissue from normal oral mucosa by using ATAS. A 4mm punch biopsy of an oral squamous cell carcinoma tumor and a control biopsy of healthy oral mucosa will be collected from 30 - 40 patients undergoing oral tumor excision. The biopsies will be examined in the research laboratory with ATAS to test tissue recognition.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
40 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis
Actual Study Start Date :
May 25, 2021
Anticipated Primary Completion Date :
Dec 1, 2024
Anticipated Study Completion Date :
Jun 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Patients diagnosed with oral squamous cell carcinoma

Procedure: Punch biopsy
Punch biopsy of oral squamous cell carcinoma tumor and a control biopsy of healthy oral mucosa are collected during primary tumor excision surgery from each recruited patient.

Outcome Measures

Primary Outcome Measures

  1. Resolution of normal and cancerous tissue [Through study completion, an average of 1 year]

    The ATAS device records a molecular spectrum of the surgical smoke generated when the collected tissue samples are processed with an electrosurgical instrument in the research laboratory. The primary outcome of the study is to test the ability of the device to correctly distinguish cancerous tissue from normal tissue based on predicted differences in the spectrum.

Secondary Outcome Measures

  1. The influence of basal cell carcinoma tumor thickness and infiltration depth on the resolution [Through study completion, an average of 1 year]

    The overall thickness of the tumor and the infiltration depth of the tumor, both presented in millimetres, can have an effect on the resolution of cancerous tissue.

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Biopsy diagnosed oral squamous cell carcinoma.

  • Tumor diameter of 2 cm or larger.

  • Operable patient that is willing to participate in the trial.

Exclusion Criteria:
  • Tumor diameter less than 2 cm.

  • Patient that is unwilling to take part in the trial.

  • Patient that is not able to understand given information concerning the trial or to give concent to take part in the trial.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Tampere University Hospital Tampere Pirkanmaa Finland 33521

Sponsors and Collaborators

  • Tampere University Hospital
  • Olfactomics Oy

Investigators

  • Study Director: Niku Oksala, M.D. Ph.D., Tampere University Hospital

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Tampere University Hospital
ClinicalTrials.gov Identifier:
NCT05902455
Other Study ID Numbers:
  • R20100L(a)
First Posted:
Jun 15, 2023
Last Update Posted:
Jun 15, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Tampere University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 15, 2023